Christoph Schwering
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Mapping Clinical Progression to Brain Atrophy in CLN2 Patients Under Cerliponase Alfa Treatment: A Prospective Neuroimaging Study.
Journal: Journal of inherited metabolic disease
Published: October 22, 2025
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa.
Journal: Frontiers in neurology
Published: October 23, 2024
Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness - A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease.
Journal: Eye and brain
Published: April 11, 2024
Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
Journal: The Lancet. Neurology
Published: March 24, 2023
Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV-Enzyme Replacement Therapy: A Case Report.
Journal: Neuropediatrics
Published: July 17, 2022
Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
Journal: The British journal of ophthalmology
Published: February 22, 2022
The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample.
Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
Published: February 02, 2022
Visual perception and macular integrity in non-classical CLN2 disease.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: November 23, 2021
Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
Journal: Journal of child neurology
Published: February 05, 2021
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
Journal: Journal of child neurology
Published: December 28, 2020
Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
Journal: Orphanet journal of rare diseases
Published: October 09, 2020
An Ophthalmic Rating Scale to Assess Ocular Involvement in Juvenile CLN3 Disease.
Journal: American journal of ophthalmology
Published: April 10, 2020
Last Updated: 09/26/2026